1,527 reports of this reaction
1.3% of all LEVETIRACETAM IN SODIUM CHLORIDE reports
#18 most reported adverse reaction
ABORTION SPONTANEOUS is the #18 most commonly reported adverse reaction for LEVETIRACETAM IN SODIUM CHLORIDE, manufactured by Actavis Pharma, Inc.. There are 1,527 FDA adverse event reports linking LEVETIRACETAM IN SODIUM CHLORIDE to ABORTION SPONTANEOUS. This represents approximately 1.3% of all 117,343 adverse event reports for this drug.
Patients taking LEVETIRACETAM IN SODIUM CHLORIDE who experience abortion spontaneous should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ABORTION SPONTANEOUS is a less commonly reported adverse event for LEVETIRACETAM IN SODIUM CHLORIDE, but still significant enough to appear in the safety profile.
In addition to abortion spontaneous, the following adverse reactions have been reported for LEVETIRACETAM IN SODIUM CHLORIDE:
The following drugs have also been linked to abortion spontaneous in FDA adverse event reports:
ABORTION SPONTANEOUS has been reported as an adverse event in 1,527 FDA reports for LEVETIRACETAM IN SODIUM CHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ABORTION SPONTANEOUS accounts for approximately 1.3% of all adverse event reports for LEVETIRACETAM IN SODIUM CHLORIDE, making it a notable side effect.
If you experience abortion spontaneous while taking LEVETIRACETAM IN SODIUM CHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.